Physician profile
Maureen C Considine
NPI 1083699516
$2,209.79
in general payments reported to CMS, 2019-2025
14 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $65.40 · 2021: $386 · 2022: $316 · 2023: $138 · 2024: $462 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $837.43 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $447.66 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $252.90 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $179.83 | 2021-2022 | |
| Sight Sciences, INC. | $163.19 | 2021-2022 | |
| Oyster Point Pharma, INC. | $76.03 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $74.80 | 2020-2022 | |
| Abbvie INC. | $59.68 | 2022-2023 | Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $43.11 | 2019-2023 | |
| Biotissue Holdings INC. | $20.84 | 2023 | |
| Aerie Pharmaceuticals, INC. | $14.86 | 2021 | |
| Shire North American Group INC | $14.42 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $13.60 | 2024 | Xdemvy |
| Glaukos Corporation | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Considine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.